Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.71 |
| ▸ | VEGFA | P15692 | 6/20 | 0.71 |
| ▸ | FLT1 | P17948 | 6/20 | 0.71 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.71 |
| ▸ | TET3 | O43151 | 1/20 | 0.54 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.54 |
| ▸ | ASPH | Q12797 | 1/20 | 0.54 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.54 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.54 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.54 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.54 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938500 | 0.89 | EGLN1 (0.55) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30790421 | 0.89 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL24579666 | 0.89 | EGLN1 (0.78) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL29188896 | 0.87 | EGLN1 (0.75) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL22588827 | 0.84 | EGLN1 (0.81) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL22239387 | 0.83 | EGLN1 (0.80) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL21565676 | 0.83 | EGLN1 (0.49) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL1921387 | 0.83 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30239178 | 0.83 | EGLN1 (1.00) | EGLN1VEGFAFLT1EGLN3TET3 | |
| SCHEMBL30957053 | 0.80 | EGLN1 (0.72) | EGLN1VEGFAFLT1EGLN3TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286918-A1 | MANUFACTURING PROCESS FOR 3,5-DICHLOROPICOLINONITRILE FOR SYNTHESIS OF VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11713298-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | AKEBIA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| WO-2022006427-A1 | MANUFACTURING PROCESS FOR 3,5-DICHLOROPICOLINONITRILE FOR SYNTHESIS OF VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210070709-A1 | Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| WO-2019217550-A1 | PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACID | AKEBIA THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070709-A1 | Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid | AASDHPPT, AADAT, ALDH7A1 | EGLN1 2285/4885VEGFA 2569/4885FLT1 2280/4885 |
| US-20230286918-A1 | MANUFACTURING PROCESS FOR 3,5-DICHLOROPICOLINONITRILE FOR SYNTHESIS OF VADADUSTAT | CYP3A4, CYP2D6, CYP2F1 | EGLN1 3285/4885VEGFA 2231/4885FLT1 1955/4885 |
| US-11713298-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | AASDHPPT, AADAT, ALDH7A1 | EGLN1 2285/4885VEGFA 2569/4885FLT1 2280/4885 |
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | EGLN1 1247/4885VEGFA 747/4885FLT1 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.